Author

C.-I. Wang

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 3 Biochemistry· 1 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 5 Research Focus:host-pathogen & immune response· 4 Assay:proteomics· 4 Organism:human· 3 Research Focus:drug response / drug discovery· 2 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1

Frequent Co-Authors

B. Wang· 3 shared L. Renia· 3 shared C. M. Poh· 2 shared C. Y.-P. Lee· 2 shared G. Carissimo· 2 shared R. S.-L. Chee· 2 shared S. Maurer-Stroh· 2 shared S. N. Amrun· 2 shared

Activity by Year

2020-2021 · peak 4/yr

Co-Author Collaboration Network

10 top collaborators · 40 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersBiochemistry

B. Wang

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Mapping the allosteric effects that define functional activity of SARS-CoV-2 specific antibodies

N. K. Tulsian, P. V. Raghuvamsi, X. Qian, G. Yue, B. D/O Shunmuganathan, F. Samsudin, Y. H. Wong, L. Jianqing, K. Purushotorman, M. K. McQueen, B. Wang, J. Lescar, C.-I. Wang, G. Anand, P. J. Bond, P. A. MacAry

This study identifies site-specific allosteric effects in SARS-CoV-2 Spike protein induced by different neutralizing antibodies, revealing dynamic features that distinguish weak from strong neutralizers.

bioRxiv · Dec 27, 2021 · PreprintBiochemistry

Neutralizing antibodies from early cases of SARS-CoV-2 infection offer cross-protection against the SARS-CoV-2 D614G variant.

C. Y.-P. Lee, S. N. Amrun, R. S.-L. Chee, Y. S. Goh, T. M. Mak, S. Octavia, N. Yeo, Z. W. Chang, M. Z. Tay, A. Torres, G. Carissimo, C. M. Poh, S.-W. Fong, B. Wang, S. Lee, , L. F. P. Ng

This study shows that antibodies from early SARS-CoV-2 infections neutralize both the original and D614G variants, though neutralizing capacity decreases over time.

bioRxiv · Oct 8, 2020 · PreprintImmunology

Bivalent binding of a fully human IgG to the SARS-CoV-2 spike proteins reveals mechanisms of potent neutralization

B. Wang, D. Asarnow, W.-H. Lee, C.-W. Huang, B. Faust, P. M. L. Ng, E. Z. X. Ngoh, M. Bohn, D. Bulkley, A. Pizzorno, H. C. Tan, C. Y. Lee, R. A. Minhat, O. Terrier, M. K. Soh, , C.-I. Wang

This study identifies a potent SARS-CoV-2 neutralizing antibody, 5A6, that binds bivalently to two RBDs on the spike protein, showing resistance to key mutations.

bioRxiv · Jul 14, 2020 · PreprintMicrobiology

Potent neutralizing antibodies in the sera of convalescent COVID-19 patients are directed against conserved linear epitopes on the SARS-CoV-2 spike protein

C. M. Poh, G. Carissimo, W. Bei, S. N. Amrun, C. Y.-P. Lee, R. S.-L. Chee, N. K.-W. Yeo, W.-H. Lee, Y.-S. Leo, M. I.-C. Chen, S.-Y. Tan, L. Y. A. Chai, S. Kalimuddin, S.-Y. Thien, B. E. Young, , L. F. Ng

The paper identifies two immunodominant linear epitopes on the SARS-CoV-2 spike protein that are targets of potent neutralizing antibodies in convalescent patient sera.

bioRxiv · Mar 30, 2020Immunology

LAG3 is a Central Regulator of NK Cell Cytokine Production

S. Narayanan, P. J. Ahl, V. B. Au, N. Kaliaperumal, S. G. Lim, C.-I. Wang, A.-M. Fairhurst, J. E. Connolly

This study shows that LAG3 inhibits cytokine production in mature NK cells by enhancing glycolytic metabolism and is upregulated by IFN-.

bioRxiv · Jan 31, 2020 · PreprintImmunology